| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14728214.11.3.445 |
| P8608 | Fatcat ID | release_bgfzdfkgmbe2texl6egea5ttxa |
| P698 | PubMed publication ID | 16939384 |
| P2093 | author name string | Joseph D Rosenblatt | |
| Luis E Raez | |||
| Eckhard R Podack | |||
| P2860 | cites work | Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial | Q27824810 |
| Revisions in the International System for Staging Lung Cancer | Q28241070 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 | ||
| Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group | Q33343072 | ||
| Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial | Q33344019 | ||
| Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. | Q33345025 | ||
| Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group | Q33348775 | ||
| Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial | Q33349736 | ||
| Dendritic cells in cancer immunotherapy | Q33932695 | ||
| Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses | Q34038753 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. | Q34545921 | ||
| Lung cancer vaccines and gene therapy | Q35179439 | ||
| GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer | Q35204553 | ||
| Cancer vaccines for the treatment and prevention of non small-cell lung cancer | Q35633764 | ||
| Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer | Q35994388 | ||
| B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes | Q36365932 | ||
| Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes | Q37094888 | ||
| Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression | Q37535549 | ||
| Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin | Q39421412 | ||
| Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation ofin vitro studies with clinical course | Q40216008 | ||
| Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS) | Q40229482 | ||
| Autologous dendritic cell vaccines for non-small-cell lung cancer. | Q40535885 | ||
| Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer | Q40535891 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule | Q40840410 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study | Q41381096 | ||
| Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene | Q41581624 | ||
| Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice | Q42538648 | ||
| Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice | Q42825677 | ||
| Platin or no platin? That is the question | Q43531557 | ||
| Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial | Q43620879 | ||
| Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy | Q44323234 | ||
| Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T | Q44499454 | ||
| Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. | Q44633976 | ||
| Docetaxel Versus Docetaxel/Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Analysis of a Multicenter, Randomized Phase III Study | Q44649982 | ||
| Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin | Q45077886 | ||
| Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). | Q50782266 | ||
| Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. | Q51024694 | ||
| Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. | Q51031723 | ||
| Lung cancer death rates in lifelong nonsmokers. | Q51804779 | ||
| Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. | Q53450116 | ||
| Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells | Q57275942 | ||
| Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation | Q59055770 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 445-459 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Present and future of lung cancer vaccines | |
| P478 | volume | 11 |
| Q35752182 | Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. |
| Q30974053 | Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. |
| Q42114592 | Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells |
| Q34161849 | MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. |
Search more.